RA Capital Management L.P. Increases Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• RA Capital Management L.P. increased its holdings in Dianthus Therapeutics by 53.6%, acquiring an additional 1,000,333 shares, making it the fund's 23rd largest position.
• Dianthus Therapeutics reported a quarterly loss of ($0.88) EPS, missing the consensus estimate, while revenue fell short of expectations at $0.19 million.
• Wall Street analysts are generally optimistic, with several firms issuing "outperform" ratings and a target price range averaging around $54.00 for the stock.

RA Capital Management L.P. lifted its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 53.6% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 2,866,733 shares of the company's stock after acquiring an additional 1,000,333 shares during the period. Dianthus Therapeutics makes up approximately 0.9% of RA Capital Management L.P.'s investment portfolio, making the stock its 23rd largest holding. RA Capital Management L.P. owned 8.92% of Dianthus Therapeutics worth $52,003,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of DNTH. Braidwell LP grew its stake in shares of Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after acquiring an additional 712,902 shares during the last quarter. Vestal Point Capital LP boosted its position in Dianthus Therapeutics by 172.2% in the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after buying an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP boosted its position in Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after buying an additional 363,500 shares during the last quarter. Candriam S.C.A. purchased a new stake in Dianthus Therapeutics in the first quarter valued at approximately $4,510,000. Finally, Janus Henderson Group PLC boosted its position in Dianthus Therapeutics by 14.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock valued at $23,607,000 after buying an additional 136,314 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Wedbush upped their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a research report on Thursday, August 21st. Robert W. Baird dropped their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Finally, William Blair assumed coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Trading Up 7.5%

Dianthus Therapeutics stock traded up $1.84 during mid-day trading on Friday, hitting $26.50. The company had a trading volume of 679,673 shares, compared to its average volume of 359,164. Dianthus Therapeutics, Inc. has a 12-month low of $13.36 and a 12-month high of $32.27. The company's fifty day moving average is $21.27 and its 200-day moving average is $20.03. The company has a market capitalization of $853.04 million, a price-to-earnings ratio of -8.15 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million during the quarter, compared to analysts' expectations of $0.87 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.